Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

SML0087

Sigma-Aldrich

MEGX

≥95% (HPLC)

Sinónimos:

MGEX, Monoethylglycinexylidide, N-(2,6-dimethylphenyl)-2-(ethylamino)acetamide, Norlidocaine

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C12H18N2O
Número de CAS:
7728-40-7
Peso molecular:
206.28
MDL number:
MFCD00098991
UNSPSC Code:
12352200
PubChem Substance ID:
329825147
NACRES:
NA.77

Quality Level

100

assay

≥95% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: 10 mg/mL, clear

storage temp.

2-8°C

SMILES string

CC1=C(NC(CNCC)=O)C(C)=CC=C1

InChI

1S/C12H18N2O/c1-4-13-8-11(15)14-12-9(2)6-5-7-10(12)3/h5-7,13H,4,8H2,1-3H3,(H,14,15)

InChI key

WRMRXPASUROZGT-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Application

MEGX has been used in an approach to improve the yield of N-dealkylated lidocaine.

Biochem/physiol Actions

MEGX is generated by hepatic cytochrome P-450 system upon oxidative de-ethylation. Measurement of MEGX by immunoassay contributes to liver function test. MEGX possesses antiarrhythmic action and therefore extends lidocaine effect.
Monoethylglycinexylidide (MEGX) is an active metabolite of lidocaine.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Ying Wang et al.
Drug design, development and therapy, 14, 1739-1747 (2020-05-23)
Lidocaine has cardiovascular and neurologic toxicity, which is dose-dependent. Due to CYP3A4-involved metabolism, lidocaine may be prone to drug-drug interactions. Given statins have the possibility of combination with lidocaine in the clinic, we established in vitro models to assess the
K Rolsted et al.
Skin pharmacology and physiology, 22(3), 124-127 (2009-01-13)
Little is known about the metabolising capacity of the human skin in relation to topically applied drugs and formulations. We chose lidocaine as a model compound since the metabolic pathways are well known from studies concerning hepatic metabolism following systemic
Optimization of reaction parameters for the electrochemical oxidation of lidocaine with a Design of Experiments approach
Gul T, et al.
Electrochimica Acta, 171, 23-28 (2015)
E J Dickey et al.
Equine veterinary journal, 40(4), 348-352 (2008-02-13)
Continuous-rate infusions (CRI) of lidocaine are often used for prolonged duration but, to date, only limited time/concentration relationships administered as a short term (24 h) CRI have been reported. To determine the time/concentration profile of lidocaine and its active metabolites
Classic Papers in Critical Care, 179-179 (2010)
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico